Wave Life Sciences has recently announced the discontinuation of its drug suvodirsen, for the treatment of a rare Duchenne Muscular Dystrophy mutation.
Duchenne Muscular Dystrophy is a progressive worsening of the skeletal and heart muscles resulting in weakness. The disorder, is due to deficient protein dystrophin, due to the mutations in the DMD gene.
The announcement of the termination of the clinical trials of suvodirsen came after the Phase 1 open-label extension (OLE) study. The trials showed no positive changes in the expression of the dystrophin from the baseline. Thus, the company has decided to halt the two trials, the O...
